After crossing t's, dotting i's, Immunocore nails down breakthrough therapy designation for lead TCR therapy
Days after tapping a new commercial head, Immunocore has scored a breakthrough therapy designation for its lead T cell receptor program, which it plans on punting to regulators for a speedy consideration in unresectable or metastatic uveal carcinoma later this year.
CEO Bahija Jallal has already nailed down $175 million to back a potential launch for tebentafusp, and earlier this week she tapped AstraZeneca vet Ralph Torbay to lead the charge. The company will approach regulators in Q3, it announced on Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.